For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Japan’s 1st Sublingual Immunotherapy Wins Approval: Torii
January 21, 2014
- Sales Reps Vied over Questionnaire Transfers in Tasigna Trial, Boss OK’ed Incentive Program: Novartis
January 21, 2014
- NBI Receives Approval for Giotrif, Sets to Enter Oncology Field
January 21, 2014
- Nissan Chemical Sues Nichi-Iko, Two Other Companies over Livalo Patent
January 21, 2014
- Novartis Sales Reps Transferred Patient Questionnaires in Investigator-Led Trial
January 20, 2014
- Japan’s First SGLT-2 Inhibitor Suglat Approved: Astellas
January 20, 2014
- Otsuka Files Abilify Once-Monthly Injectable in Japan
January 17, 2014
- Alcon Japan Merges with CIBA Vision
January 17, 2014
- MTPC Files Telavic for Chronic Hepatitis C Genotype 2
January 17, 2014
- FDA Raises Concerns about Ranbaxy’s India Plant with Form 483
January 16, 2014
- Japan Added as Mogamulizumab PIII Study Site for CTCL Patients: Kyowa Kirin
January 16, 2014
- Takeda to Sell BIKEN Varicella Vaccine from February
January 16, 2014
- Swiss Novartis to “Fully Address” Flaws Leading to Criminal Complaint Filing
January 16, 2014
- Seikagaku Confirms Winning in Gel-One Patent Infringement Lawsuit Following Genzyme’s Withdrawal of Appeal
January 16, 2014
- Special Drug Use-Result Survey for Plavix Finds 0.19% Incidence of Cerebral Hemorrhage in Cerebral Infarction in Acute Phase
January 16, 2014
- Takeda Appoints Former GSK Exec as Head of CNS Drug Discovery Unit
January 15, 2014
- Shionogi Inc., Hisamitsu Unit to Copromote Hot Flashes Drug in US
January 15, 2014
- Daiichi Sankyo, 2 US Startups to Collaborate on Research of Academia-Oriented Seeds
January 14, 2014
- Ethical Drug Sales Up 0.8% in November Due to New Drug Launches and Lifting of 14-Day Prescription Limit: Crecon Report
January 14, 2014
- Pharma Biz Leaders Say New Price Cut Rule for Long-Listed Products a Painful Blow
January 10, 2014
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…